Home / Science / AI Vaccine Targets Broad Coronavirus Threats
AI Vaccine Targets Broad Coronavirus Threats
27 Jun
Summary
- AI-designed vaccine shows promise against SARS-CoV-2 and related coronaviruses.
- Initial human trial found the vaccine safe and well-tolerated in adults.
- The vaccine aims to provide broad protection against future viral outbreaks.
Researchers have developed an experimental vaccine, pEVAC-PS, designed with AI to offer broad protection against various coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential. The vaccine employs a synthetic "super-antigen" to train the immune system to recognize common features across different coronaviruses.
In a recent Phase 1 clinical trial involving 39 healthy adults, pEVAC-PS was found to be safe and well-tolerated, with no significant side effects reported. The DNA vaccine was administered using a needle-free intradermal injection system, which could simplify delivery and reduce risks.
The trial indicated that the vaccine generated immune responses against SARS-CoV-2 and SARS viruses, as well as against bat coronaviruses that could potentially cause future outbreaks. This "future-proofed" approach could reduce the need for frequent vaccine reformulation, a limitation of current reactive strategies.
While these findings are encouraging, experts emphasize that this was a small trial focused on safety. Larger studies are necessary to confirm the vaccine's effectiveness in preventing infection. If successful, AI-designed vaccines could significantly enhance global preparedness for future pandemics by targeting entire virus families.
